Get the Stockscreener App
20.35
1.45%
0.29
After Hours:
20.31
-0.04
-0.20%
Arrivent Biopharma Inc stock is traded at $20.35, with a volume of 164.67K.
It is up +1.45% in the last 24 hours and up +3.88% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$20.06
Open:
$19.88
24h Volume:
164.67K
Relative Volume:
0.52
Market Cap:
$840.08M
Revenue:
-
Net Income/Loss:
$-136.98M
P/E Ratio:
-5.0622
EPS:
-4.02
Net Cash Flow:
$-126.63M
1W Performance:
-1.64%
1M Performance:
+3.88%
6M Performance:
-0.59%
1Y Performance:
-23.47%
1-Day Range:
$19.88
$20.60
1-Week Range:
$19.88
$21.11
52-Week Range:
$15.47
$30.41
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.35 | 828.10M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Avoiding Lag: Real-Time Signals in (AVBP) Movement - news.stocktradersdaily.com
ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam - MSN
Is ArriVent BioPharma Inc. stock in correction or buying zoneCEO Change & Smart Money Movement Alerts - newser.com
Can ArriVent BioPharma Inc. stock outperform in 2025 bull marketEarnings Overview Summary & Momentum Based Trading Signals - newser.com
Best data tools to analyze ArriVent BioPharma Inc. stockJuly 2025 Big Picture & Smart Swing Trading Alerts - newser.com
How institutional ownership impacts ArriVent BioPharma Inc. stockWeekly Trade Recap & Stepwise Entry and Exit Trade Signals - newser.com
Will ArriVent BioPharma Inc. stock gain from lower inflationWeekly Profit Recap & Reliable Volume Spike Trade Alerts - newser.com
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsGap Down & High Yield Equity Trading Tips - newser.com
Can momentum traders help lift ArriVent BioPharma Inc.Portfolio Value Summary & AI Forecasted Stock Moves - newser.com
Published on: 2025-11-19 02:02:03 - newser.com
Is ArriVent BioPharma Inc. stock a defensive play in 20252025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
Why Red River Bancshares, Inc. stock attracts strong analyst attention - newser.com
Evaluating ArriVent BioPharma Inc. with trendline analysisWeekly Risk Summary & Free Real-Time Market Sentiment Alerts - newser.com
Analyzing ArriVent BioPharma Inc. with risk reward ratio chartsJuly 2025 Decliners & Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-15 15:01:05 - newser.com
Why ArriVent BioPharma Inc. stock is favored by pension fundsLong Setup & Accurate Entry/Exit Alerts - newser.com
Momentum divergence signals in ArriVent BioPharma Inc. chartWeekly Stock Recap & Real-Time Volume Analysis - newser.com
What is the fair value of ArriVent BioPharma Inc. stock now2025 Earnings Impact & Fast Gain Stock Tips - Fundação Cultural do Pará
What is HC Wainwright’s Forecast for AVBP FY2025 Earnings? - Defense World
We Think ArriVent BioPharma (NASDAQ:AVBP) Needs To Drive Business Growth Carefully - Yahoo Finance
Real time pattern detection on ArriVent BioPharma Inc. stockWeekly Trade Recap & Pattern Based Trade Signal System - newser.com
ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target - TipRanks
ArriVent Biopharma : Corporate Presentation November 2025 - MarketScreener
ArriVent BioPharma’s Promising Trial Results and Strategic Developments Drive Buy Rating - TipRanks
Discipline and Rules-Based Execution in AVBP Response - news.stocktradersdaily.com
ArriVent BioPharma Reports Q3 2025 Financial Results - TipRanks
ArriVent BioPharma Reports Third Quarter 2025 Financial Results - The Globe and Mail
ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street - Investing.com Canada
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):